Trial
NCT01677572
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Biogen
Collaborators
—
Condition
Alzheimer's Disease
Intervention
Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)
Why stopped
Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and NCT02484547) and not based on safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-08-03